{"id":8069,"date":"2025-09-27T20:56:52","date_gmt":"2025-09-27T20:56:52","guid":{"rendered":"https:\/\/polikistikover.net\/yeni\/?page_id=8069"},"modified":"2025-11-25T01:31:02","modified_gmt":"2025-11-25T01:31:02","slug":"polikistik-over-sendromu-ve-kan-yaglari-kolesterol-ve-trigliserid","status":"publish","type":"page","link":"https:\/\/polikistikover.net\/yeni\/polikistik-over-sendromu-ve-kan-yaglari-kolesterol-ve-trigliserid\/","title":{"rendered":"Polikistik Over Sendromu ve Kan Ya\u011flar\u0131 (Kolesterol ve Trigliserid)"},"content":{"rendered":"\n<p>Kalp ve damar hastal\u0131\u011f\u0131&nbsp;(kalp, beyin ve bacaklara oksijen ta\u015f\u0131yan damarlar\u0131n t\u0131kanmas\u0131 veya daralmas\u0131) ihtimalini artt\u0131ran \u00f6zelliklerden 2 tanesi kan ya\u011flar\u0131ndan kolesterol ve trigliserid ile ilgilidir.<\/p>\n\n\n\n<p class=\"has-text-align-center\"><strong>A\u015fa\u011f\u0131daki<mark style=\"background-color: rgba(0, 0, 0, 0);\" class=\"has-inline-color has-dark-blue-color\"><b> <\/b><\/mark><\/strong><mark style=\"background-color: rgba(0, 0, 0, 0);\" class=\"has-inline-color has-dark-blue-color\"><b>\u00f6zelliklerden en az 3 tanesi biraraya gelerek metabolik sendromu olu\u015fturmaktad\u0131r(1,2,3,4);<\/b><\/mark><\/p>\n\n\n\n<p><strong><mark style=\"background-color:#f91108\" class=\"has-inline-color\">1-<\/mark><\/strong>Kan bas\u0131nc\u0131 y\u00fcksekli\u011fi (\u2265 130 \/85 mmHg)<\/p>\n\n\n\n<p><strong><mark style=\"background-color:#f60505\" class=\"has-inline-color\">2-<\/mark><\/strong>V\u00fccudun \u00fcst k\u0131sm\u0131nda yani kar\u0131n ve bel b\u00f6lgesinde&nbsp;bulunan ya\u011f miktar\u0131n\u0131n artmas\u0131 (bel \u00e7evresi&nbsp;\u2265 80 cm)<\/p>\n\n\n\n<p><strong><mark style=\"background-color:#f70909\" class=\"has-inline-color\">3-<\/mark><\/strong>A\u00e7l\u0131k kan \u015fekeri (glukoz) y\u00fcksekli\u011fi (\u2265 100 mg\/dL)<\/p>\n\n\n\n<p><strong><mark style=\"background-color:#f80e0e\" class=\"has-inline-color\">4-<\/mark>Kan ya\u011flar\u0131ndan faydal\u0131 olan HDL-C miktar\u0131n\u0131n azalmas\u0131 (\u2264 50 mg\/dL)<\/strong><\/p>\n\n\n\n<p><strong><mark style=\"background-color:#fa0b0b\" class=\"has-inline-color\">5-<\/mark>Kan ya\u011flar\u0131ndan trigliserid miktar\u0131n\u0131n artmas\u0131 (&nbsp;\u2265150 mg\/dL)<\/strong><\/p>\n\n\n\n<p class=\"has-text-align-center\"><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-dark-pink-color\">Polikistik over sendromu olan kad\u0131nlarda metabolik sendrom daha s\u0131k g\u00f6r\u00fclmektedir.(5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29).<\/mark><\/strong><\/p>\n\n\n\n<p>Polikistik over sendromu olan kad\u0131nlar\u0131n bir k\u0131sm\u0131nda faydal\u0131 bir ya\u011f olan HDL-kolesterol&nbsp;kan dola\u015f\u0131m\u0131nda normalden daha az miktarda bulunurken, trigliserid ve LDL-kolesterol ise normalden daha fazla miktarlarda bulunmaktad\u0131r(31,32,33,34). <\/p>\n\n\n\n<p>Polikistik over sendromu olan kad\u0131nlar\u0131n b\u00fcy\u00fck bir k\u0131sm\u0131nda g\u00f6r\u00fclen ins\u00fclin direnci HDL-kolesterol ve trigliserid miktarlar\u0131n\u0131 etkilemektedir. <\/p>\n\n\n\n<p>LDL-kolesterol miktar\u0131ndaki art\u0131\u015f ise daha \u00e7ok erkeklik hormonlar\u0131n\u0131n (androgen) etkisinin fazla olmas\u0131 (hiperandrogenism) ile ili\u015fkilidir(30,31,32,33,34).<\/p>\n\n\n\n<figure class=\"wp-block-embed aligncenter is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe loading=\"lazy\" title=\"#polikistikover #ya\u011flanmaart\u0131\u015f\u0131 #kar\u0131nya\u011flanmas\u0131 #karaci\u011ferya\u011flanmas\u0131 #enerjikayna\u011f\u0131ya\u011flar #ya\u011flanma\" width=\"1320\" height=\"743\" src=\"https:\/\/www.youtube.com\/embed\/fhTdeSZj-po?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n<\/div><\/figure>\n\n\n\n<p class=\"has-text-align-center\"><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-dark-blue-color\">Polikistik over sendromu olan kad\u0131nlar\u0131n kalp ve damar hastal\u0131klar\u0131 a\u00e7\u0131s\u0131ndan mutlaka de\u011ferlendirilmesi gerekmektedir!<\/mark><\/strong><\/p>\n\n\n\n<p class=\"has-text-align-center\"> <strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-dark-pink-color\">Bu kad\u0131nlar\u0131n \u00e7ok gen\u00e7 ya\u015flarda adet d\u00fczensizli\u011fi, \u00e7ocuk iste\u011fi, t\u00fcylenme art\u0131\u015f\u0131, sivilce ve sa\u00e7 d\u00f6k\u00fclmesi i\u00e7in kad\u0131n do\u011fum uzman\u0131na ya da cildiye uzman\u0131na ba\u015fvurmalar\u0131 asl\u0131nda y\u00fcksek olan kalp ve damar hastal\u0131klar\u0131 ve metabolik sendrom riskinin erken ya\u015flarda tespit edilmesi a\u00e7\u0131s\u0131ndan \u00f6nemli bir avantaj sa\u011flamaktad\u0131r. <\/mark><\/strong><\/p>\n\n\n\n<p class=\"has-text-align-center\">F<strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-dark-pink-color\">akat, maalesef \u00e7o\u011funlukla kendi bran\u015flar\u0131n\u0131n d\u0131\u015f\u0131nda oldu\u011fu i\u00e7in ya da hastan\u0131n ba\u015fvuru \u015fikayetiyle ilgili olmad\u0131\u011f\u0131 i\u00e7in kad\u0131n do\u011fum ve cildiye uzmanlar\u0131 \u00e7ok basit bir \u015fekilde \u00f6l\u00e7\u00fclebilen kan bas\u0131nc\u0131, bel ve basen \u00e7evresi \u00f6l\u00e7\u00fcm\u00fcn\u00fc \u00e7o\u011funlukla yapmamaktad\u0131r.<\/mark><\/strong><\/p>\n\n\n\n<p class=\"has-text-align-center\"><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-dark-pink-color\"> \u00c7ok gen\u00e7 ya\u015flarda doktora ba\u015fvurmalar\u0131na ra\u011fmen bu kad\u0131nlarda sorun \u00e7\u0131kma ihtimali y\u00fcksek olan kan ya\u011flar\u0131 (trigliserid, kolesterol), ins\u00fclin direnci, bozulmu\u015f \u015feker tolerans\u0131 ve \u015feker hastal\u0131\u011f\u0131 testleri de \u00e7o\u011funlukla yap\u0131lmamaktad\u0131r.<\/mark><\/strong><\/p>\n\n\n\n<p class=\"has-text-align-center\"><strong>Kaynaklar<\/strong><\/p>\n\n\n\n<p><strong>\u2217<\/strong>1-Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement.&nbsp;Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F; American Heart Association; National Heart, Lung, and Blood Institute.&nbsp;Circulation. 2005 Oct 25;112(17):2735-52.<\/p>\n\n\n\n<p>2-National Institues of Health. Third Report of the Cholesterol Education Program Expert Panel on Detection, Ealuation, and Treatment of High blood Cholesterol in Adults (Adult Treatment Panel III). NIH Publication 01-3670. Bethesda, MD: &nbsp;National Institues of Health. 2001.<\/p>\n\n\n\n<p>3-Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR).&nbsp;Balkau B, Charles MA. Diabet Med. 1999 May;16(5):442-3.<\/p>\n\n\n\n<p>4-The metabolic syndrome\u2013a new worldwide definition. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. Lancet. 2005 Sep 24-30;366(9491):1059-62.<\/p>\n\n\n\n<p>5-The prevalence of metabolic disorders in various phenotypes of polycystic ovary syndrome: a community based study in Southwest of Iran. Tehrani FR, Rashidi H, Khomami MB, Tohidi M, Azizi F. Reprod Biol Endocrinol. 2014&nbsp;&nbsp;Sep 16;12:89.<\/p>\n\n\n\n<p>6-The frequency of metabolic syndrome is higher among PCOS Brazilian women with menstrual irregularity plus hyperandrogenism. Melo AS, Vieira CS, Romano LG, Ferriani RA, Navarro PA.&nbsp;Reprod Sci. 2011&nbsp;Dec;18(12):1230-6.<\/p>\n\n\n\n<p>7-Age- and body mass index-related differences in the prevalence of metabolic syndrome in women with polycystic ovary syndrome. Panidis D, Tziomalos K, Macut D, Kandaraki EA, Tsourdi EA, Papadakis E, Katsikis I.&nbsp;Gynecol Endocrinol. 2013&nbsp;Oct;29(10):926-30.<\/p>\n\n\n\n<p>8-Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria. Shroff R, Syrop CH, Davis W, Van Voorhis BJ, Dokras A.&nbsp;Fertil Steril. 2007&nbsp;Nov;88(5):1389-95.<\/p>\n\n\n\n<p>9-Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. Coviello AD, Legro RS, Dunaif A.&nbsp;J Clin Endocrinol Metab. 2006&nbsp;Feb;91(2):492-7.<\/p>\n\n\n\n<p>10-Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE.&nbsp;J Clin Endocrinol Metab. 2005&nbsp;Apr;90(4):1929-35.<\/p>\n\n\n\n<p>11-Screening women with polycystic ovary syndrome for metabolic syndrome. Dokras A, Bochner M, Hollinrake E, Markham S, Vanvoorhis B, Jagasia DH.&nbsp;Obstet Gynecol. 2005&nbsp;Jul;106(1):131-7.<\/p>\n\n\n\n<p>12-Prominent role of low HDL-cholesterol in explaining the high prevalence of the metabolic syndrome in polycystic ovary syndrome. Gambineri A, Repaci A, Patton L, Grassi I, Pocognoli P, Cognigni GE, Pasqui F, Pagotto U, Pasquali R.&nbsp;Nutr Metab Cardiovasc Dis. 2009&nbsp;Dec;19(11):797-804.<\/p>\n\n\n\n<p>13-Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L.&nbsp;Metabolism. 2003&nbsp;Jul;52(7):908-15.<\/p>\n\n\n\n<p>14-Prevalence of the metabolic syndrome in German women with polycystic ovary syndrome. Hahn S, Tan S, Sack S, Kimmig R, Quadbeck B, Mann K, Janssen OE. Exp Clin Endocrinol Diabetes. 2007&nbsp;Feb;115(2):130-5.<\/p>\n\n\n\n<p>15-Prevalence of the metabolic syndrome in women with a previous diagnosis of polycystic ovary syndrome: long-term follow-up. Hudecova M, Holte J, Olovsson M, Larsson A, Berne C, Sundstrom-Poromaa I.&nbsp;Fertil Steril. 2011 Nov;96(5):1271-4.<\/p>\n\n\n\n<p>16-The metabolic syndrome in young Korean women with polycystic ovary syndrome. Park HR, Choi Y, Lee HJ, Oh JY, Hong YS, Sung YA.&nbsp;Diabetes Res Clin Pract. 2007&nbsp;&nbsp;Sep;77 Suppl 1:S243-6.<\/p>\n\n\n\n<p>17-Using the androgen excess-PCOS society criteria to diagnose polycystic ovary syndrome and the risk of metabolic syndrome in adolescents. Roe AH, Prochaska E, Smith M, Sammel M, Dokras A.&nbsp;J Pediatr. 2013&nbsp;May;162(5):937-41.<\/p>\n\n\n\n<p>18-Prevalence and risk of metabolic syndrome&nbsp;in adolescent Indian girls with polycystic ovary syndrome&nbsp;using the 2009 \u2018joint interim criteria\u2019.&nbsp;Bhattacharya SM, Jha A. J Obstet Gynaecol Res. 2011 Oct; 37(10): 1303-7.<\/p>\n\n\n\n<p>19-Cardiovascular risks and metabolic syndrome in Hong Kong Chinese women with polycystic ovary syndrome. Cheung LP, Ma RC, Lam PM, Lok IH, Haines CJ, So WY, Tong PC, Cockram CS, Chow CC, Goggins WB.&nbsp;Hum Reprod. 2008&nbsp;&nbsp;Jun;23(6):1431-8.<\/p>\n\n\n\n<p>20-Metabolic syndrome in polycystic ovary syndrome. Carmina E.&nbsp;Minerva Ginecol. 2006&nbsp;Apr;58(2):109-14.<\/p>\n\n\n\n<p>21-Metabolic syndrome in young Czech women with polycystic ovary syndrome.&nbsp;Vrb\u00edkov\u00e1 J, Vondra K, Cibula D, Dvor\u00e1kov\u00e1 K, Stanick\u00e1 S, Sr\u00e1mkov\u00e1 D, SindelkaG, Hill M, Bendlov\u00e1 B, Skrha J.&nbsp;Hum Reprod. 2005&nbsp;Dec; 20(12):3328-32.<\/p>\n\n\n\n<p>22-Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. Vural B, Caliskan E, Turkoz E, Kilic T, Demirci A.&nbsp;Hum Reprod. 2005&nbsp;Sep;20(9):2409-13.<\/p>\n\n\n\n<p>23-Biochemical hyperandrogenism is associated with metabolic syndrome independently of adiposity and insulin resistance in Romanian polycystic ovary syndrome patients. Albu A, Radian S, Fica S, Barbu CG.&nbsp;Endocrine. 2015&nbsp;Mar;48(2):696-704.<\/p>\n\n\n\n<p>24-Polycystic ovary syndrome and metabolic syndrome in Indigenous Australian women. Boyle J, Cunningham J, Norman RJ, Dunbar T, O\u2019Dea K.&nbsp;Intern Med J. 2015&nbsp;&nbsp;Dec;45(12):1247-54.<\/p>\n\n\n\n<p>25-Phenotype and metabolic profile of South Asian women with polycystic ovary syndrome (PCOS): results of a large database from a specialist Endocrine Clinic.&nbsp;Wijeyaratne CN, Seneviratne Rde A, Dahanayake S, Kumarapeli V, Palipane E, Kuruppu N, Yapa C, Seneviratne Rde A, Balen AH.&nbsp;Hum Reprod. 2011 Jan;26(1):202-13.<\/p>\n\n\n\n<p>26-The risk of metabolic syndrome&nbsp;in polycystic ovary syndrome: A systematic review and meta-analysis.&nbsp;Behboudi-Gandevani S, Amiri M, Bidhendi Yarandi R, Noroozzadeh M, Farahmand M, Rostami Dovom M, Ramezani Tehrani F.&nbsp;Clin Endocrinol (Oxf). 2018&nbsp;&nbsp;Feb;88(2):169-184.<\/p>\n\n\n\n<p>27-&nbsp;Metabolic syndrome in polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression.&nbsp;Lim SS, Kakoly NS, Tan JWJ, Fitzgerald G, Bahri Khomami M, Joham AE, Cooray SD, Misso ML, Norman RJ, Harrison CL, Ranasinha S, Teede HJ, Moran LJ.&nbsp;Obes Rev. 2019 Feb;20(2):339-352.<\/p>\n\n\n\n<p>28-Metabolic Syndrome in Polycystic Ovary Syndrome. Pasquali R.&nbsp;Front Horm Res. 2018;49:114-130.<\/p>\n\n\n\n<p>29-Beyond fertility: polycystic ovary syndrome and long-term health. Cooney LG, Dokras A.&nbsp;Fertil Steril. 2018&nbsp;Oct;110(5):794-809.<\/p>\n\n\n\n<p>30-Normo- and hyperandrogenic women with polycystic ovary syndrome exhibit an adverse metabolic profile through life. Pinola P,&nbsp;Puukka K, Piltonen TT, Puurunen J, Vanky E, Sundstr\u00f6m-Poromaa I, Stener-Victorin E, Lind\u00e9n Hirschberg A,Ravn P, Skovsager Andersen M, Glintborg D, Mellembakken JR, Ruokonen A, Tapanainen JS, Morin-Papunen LC.&nbsp;Fertil Steril. 2017 Mar;107(3):788-795.<\/p>\n\n\n\n<p>31-Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Conway GS, Agrawal R, Betteridge DJ, Jacobs HS.&nbsp;Clin Endocrinol (Oxf). 1992&nbsp;Aug;37(2):119-25.<\/p>\n\n\n\n<p>32-Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. Talbott E, Clerici A, Berga SL, Kuller L, Guzick D, Detre K, Daniels T, Engberg RA.&nbsp;J Clin Epidemiol. 1998&nbsp;May;51(5):415-22.<\/p>\n\n\n\n<p>33-A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. Valkenburg O, Steegers-Theunissen RP, Smedts HP, Dallinga-Thie GM, Fauser BC, Westerveld EH, Laven JS.&nbsp;J Clin Endocrinol Metab. 2008&nbsp;Feb;93(2):470-6.<\/p>\n\n\n\n<p>34-Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Wild RA, Rizzo M, Clifton S, Carmina E.Fertil Steril. 2011&nbsp;Mar 1;95(3):1073-9.e1-11.<\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kalp ve damar hastal\u0131\u011f\u0131&nbsp;(kalp, beyin ve bacaklara oksijen ta\u015f\u0131yan damarlar\u0131n t\u0131kanmas\u0131 veya daralmas\u0131) ihtimalini artt\u0131ran \u00f6zelliklerden 2 tanesi kan ya\u011flar\u0131ndan kolesterol ve trigliserid ile ilgilidir. A\u015fa\u011f\u0131daki \u00f6zelliklerden en az 3 tanesi biraraya gelerek metabolik sendromu olu\u015fturmaktad\u0131r(1,2,3,4); 1-Kan bas\u0131nc\u0131 y\u00fcksekli\u011fi (\u2265 130 \/85 mmHg) 2-V\u00fccudun \u00fcst k\u0131sm\u0131nda yani kar\u0131n ve bel b\u00f6lgesinde&nbsp;bulunan ya\u011f miktar\u0131n\u0131n artmas\u0131 (bel [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-8069","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/polikistikover.net\/yeni\/wp-json\/wp\/v2\/pages\/8069","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/polikistikover.net\/yeni\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/polikistikover.net\/yeni\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/polikistikover.net\/yeni\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/polikistikover.net\/yeni\/wp-json\/wp\/v2\/comments?post=8069"}],"version-history":[{"count":7,"href":"https:\/\/polikistikover.net\/yeni\/wp-json\/wp\/v2\/pages\/8069\/revisions"}],"predecessor-version":[{"id":12938,"href":"https:\/\/polikistikover.net\/yeni\/wp-json\/wp\/v2\/pages\/8069\/revisions\/12938"}],"wp:attachment":[{"href":"https:\/\/polikistikover.net\/yeni\/wp-json\/wp\/v2\/media?parent=8069"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}